The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis

Circulation

Volumn 94, Issue 8, 1996, Pages 1913-1918

  Jukema, J Wouter ^a   Van Boven, Ad J ^b   Groenemeijer, Björn ^c   Zwinderman, Aeilko H ^d   Reiber, Johan H C ^a   Bruschke, Albert V G ^a   Henneman, J A ^e   Molhoek, G P ^f   Bruin, T ^c   Jansen, H ^g   Gagné, Eric ^h   Hayden, Michael R ^h   Kastelein, John J P ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e Location Alkmaar   (Netherlands)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

^g ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

atherosclerosis; genes; lipoproteins

Indexed keywords

ARGININE; ASPARTIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL; LIPID; LIPOPROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; FAMILY HISTORY; GENE MUTATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; AMINO ACID SEQUENCE; ANGIOCARDIOGRAPHY; BLOOD; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; GENE; GENETICS; HETEROZYGOTE; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY;

AMINO ACID SEQUENCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; GENES; HETEROZYGOTE; HUMANS; LIPIDS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MIDDLE AGED; MUTATION; PRAVASTATIN;

EID: 0030587872     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.8.1913     Document Type: Article

References (17)

1. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver C, Beaudet AI, Sly WS, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill Book Co; 1989:1165-1180.
2. Mulder M, Lombardi P, Jansen H, van Berkel TJC, Frants RR, Havekes LM. Low density lipoprotein receptor internalizes LDL and VLDL that are bound to heparan sulphate proteoglycans via lipoprotein lipase. J Biol Chem. 1993;268:9369-9375.
3. Ma Y, Liu MS, Ginzinger D, Frohlich J, Brunzell JD, Hayden MR. Gene environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser 172→Cys mutation in the lipoprotein lipase gene. J Clin Invest. 1993;91:1953-1958.
4. 291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet. 1995;10:28-34.
5. Bijvoet, SM, Gagne SE, Moorjani S, Gagne C, Henderson HE, Fruchart J, Dallongeville J, Alaupovic P, Prins M, Kastelein JJP, Hayden MR. Significant Alterations in Plasma Lipoproteins and Apoproteins Before the Age of 40 in Heterozygotes for LPL Deficiency. University of Amsterdam, The Netherlands; 1994. Thesis.
6. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470-476.
7. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
8. 9 Asn): functional implications and prevalence in normal and hyperlipidemic subjects. Anerioscler Thromb Vase Biol. 1995;15:468-478.
9. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the regression growth evaluation statin study (REGRESS). Circulation. 1995;91:2528-2540.
10. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
11. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
12. Williams KJ, Petrie KA, Brocia RW, Swenson TL. Lipoprotein lipase modulates net secretory output off apolipoprotein B in vitro. J Clin Invest. 1991;88:1300-1306.
13. Buchwald H, Matts JP, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, Castaneda-Zubiga WR, Hunter DW, Pearce MB, Bissett JK, Edmiston WA, Sawin HS, Weber FJ, Varco RL, Campbell GS, Yellin AE, Smink RD, Long JM, Hansen BJ, Chalmers TC, Meier P, Stamler J, for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268:1429-1433.
14. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87;1067-1075.
15. Azen SP, Mack WJ, Cashin-Hemphill L, LaBree L, Shircore AM, Selzer RH, Blankenhorn DH, Hodis HN. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation. 1996;93:34-41.
16. Harrison DG, Armstrong ML, Freimann PC, Heistad DD. Restoration of endothelium-dependent arterial relaxation by dietary treatment of atherosclerosis. Circulation. 1987;80:1808-1811.
17. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.